Shareholders Genmab A/S

This Privacy Policy explains how Genmab A/S (“We”, “Us”) processes your personal data in our administration of our shareholders including your participation in Genmab’s Annual General Meeting.


1) DATA CONTROLLER

The entity responsible for the processing of your personal data is:

Genmab A/S (CVR no. 21023884)
Kalvebod Brygge 43,
DK-1560 Copenhagen V
www.genmab.com

Contact details (if you have inquiries and/or questions to our processing of your personal data): [email protected].


2) USE OF PERSONAL DATA

We may use your personal data for the following purposes: 

Administration of shareholders 

We collect your personal data in order for Us to:  

  • Keep a register of our shareholders. 
  • Share relevant news and notices, e.g. the annual report and information regarding our General Meeting as requested by you.  
  • Document shareholding for financial reporting. 
  • Follow up on general requests or questions submitted by you. 

For these purposes, we collect the following data about you: Name, address, email address, telephone number, ip-address, bank, registration number, account number, information on communication preferences, Genmab stock portfolio information, information relating to the General Meeting (e.g. your attendance at the General Meeting and your voting), content of your question if you contact Genmab and any other information relevant to your shareholding. 
 
Depending on the circumstance, we may share your data with the following recipients:  

  • Group entities 
  • Euronext Securities (VP Securities A/S) 
  • Auditors 
  • The public through publication of the calling of the General Meeting and the passing of the General Meeting (e.g. in case a shareholder proposal is included) on Genmab’s corporate website www.genmab.com in accordance with applicable rules and mailing list distribution 
  • Nasdaq Copenhagen A/S 
  • Public authorities, e.g. the Danish Financial Supervisory Authority’s database.  

We may process your personal data described above based on the following legal bases: 

We process the personal data to comply with our legal obligations as set out in the Danish Companies Act cf. GDPR art. 6 (1) (c). 

Collection and processing of personal data will be based on our legitimate interests as we need to be able to identify and manage our shareholders, cf. GDPR art. 6 (1) (f). 

You have given your consent to the processing of your personal data for one or more specific purposes and indicated in the informed consent form presented and signed by you upon entry into the Genmab InvestorPortal, cf.  Art. 6 (1) litra a of the GDPR.                                                                                                                               

General Meeting

We collect your personal data in order for Us to:  

  • Register your participation and/or your grant of a proxy or voting (incl. by post). 
  • Register your question(s) or proposal(s) prior to/at the General Meeting. The question(s)/proposal(s) may be part of the agenda and the minutes from the General Meeting and may include your name and any opinion expressed. You cannot ask that your question is not recorded if you choose to ask a question at the General Meeting.  
  • Webcast and record the General Meeting to make it available on Genmab’s corporate website (live and archived). The webcast may also be included in a General Meeting shareholder portal. 

For these purposes, we collect the following data about you: Name, address, email address, telephone number, ip-address, information on communication preferences, Genmab stock portfolio information, content of your question if you contact Genmab, information relating to the General Meeting (e.g. your attendance at the General Meeting, your voting, question, comment and/or proposal at the General Meeting and the video/audio recording of the General Meeting including the information therein) and any other information relevant to the shareholding. 

Depending on the circumstance, we may share your data with the following recipients:  

  • Group entities 
  • Euronext Securities (VP Securities A/S) 
  • Get Visual (AV supplier)  
  • Auditors

We may process your personal data described above based on the following legal bases: 

The minutes from the General Meetings are prepared in accordance with the Danish Companies Act, and the processing of shareholders’ personal data thus takes place in order for us to comply with our legal obligation, cf. GDPR art. 6 (1) (c). 

The recording and collection of your personal data during our General Meetings will be based on our legitimate interest in being able to identify you as a shareholder or proxy holder in order to enable you to exercise your rights at the General Meeting, cf. GDPR art. 6 (1) (f). 

3) TRANSFERS TO COUNTRIES OUTSIDE THE EU/EEA 

Your personal data may be transferred within the EEA or to countries outside the EEA, that are not deemed to provide an adequate level of protection of your personal data compared to the EEA. Instead we have provided appropriate safeguards as required by GDPR art. 49 (1) through EU Standard Contractual Clauses. 

You may obtain a copy of the EU standard contractual clauses by contacting Us at: [email protected]

 
4) RETENTION OF YOUR PERSONAL INFORMATION 

We will not keep your personal data longer than required by applicable law. 

We will retain your personal data related to Genmab’s shareholder register for up to six (6) years calculated from the date you no longer hold Genmab shares. 

Webcast: Will be deleted from Genmab’s corporate website after the minutes from the General Meeting has been approved. Genmab will keep it hosted for one year (1) for documentation purposes. 

Calling and Passing of the General Meeting: Will be kept infinitely for documentation purposes. 

Minutes of the General Meeting: Will be kept infinitely for documentation purposes. 

We store the minutes until it is no longer necessary for the purpose of documenting the discussions and resolutions passed at the General Meeting. 

Company Announcement of the Calling and Passing of the General Meeting: Will be kept five (5) years on Genmab’s corporate website and internally infinitely for documentation purposes.  

Submission of questions/proposals and notification of participation, granting a proxy and voting incl. by proxy or post for the General Meeting: If the shareholder contacts us directly, we will also store this information for up to six (6) years for documentation purposes. 

Questions and correspondence if you contact Genmab as a shareholder: Will be kept for a maximum of two (2) years to perform outreach to those who have expressed an interest in learning about Genmab’s business, providing you with clear and timely communication about the company’s activities to understand what kind of information level is already communicated to you. 

 
5) YOUR RIGHTS 

In general, you have the following rights: 

  • You have the right to request access to and rectification or erasure of your personal data. 
  • You also have the right to object to the processing of your personal data and have the processing of your personal data restricted. 
  • In particular, you have an unconditional right to object to the processing of your personal data for direct marketing purposes. 
  • If processing of your personal information is based on your consent, you have the right to withdraw your consent at any time. Your withdrawal will not affect the lawfulness of the processing carried out before you withdrew your consent. 
  • You have the right to receive your personal information in a structured, commonly used and machine-readable format (data portability). 
  • You may always lodge a complaint with a data protection supervisory authority, e.g. The Danish Data Protection Agency. 

There may be conditions or limitations on these rights. It is therefore not certain for example you have the right of data portability in the specific case – this depends on the specific circumstances of the processing activity. 


Last updated: February 2022


Back to top

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.